Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010
Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter - MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter - Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
August 11, 2010 / Pharmacogenomics Reporter - Agendia Hoping Fourth FDA Clearance for MammaPrint Convinces Payors
December 23, 2009 / Pharmacogenomics Reporter - St. Gallen's Recommendations May Impact Adoption of Leading Breast Cancer Genetic Tests
July 8, 2009 / Pharmacogenomics Reporter